Astrazeneca (AZN) Gross Margin Growth (5y) (2014 - 2026)
Astrazeneca (AZN) Gross Margin Growth (5y) (2014 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
| 1 |
Gsk |
93,699,046.73 Bn |
93,699,041.77 Bn |
7.76 Bn |
| 2 |
Eli Lilly |
1,012.06 Bn |
1,006.77 Bn |
16.22 Bn |
| 3 |
Johnson & Johnson |
560.67 Bn |
538.62 Bn |
15.96 Bn |
| 4 |
AbbVie |
402.20 Bn |
392.85 Bn |
10.78 Bn |
| 5 |
Merck |
298.59 Bn |
292.94 Bn |
12.09 Bn |
| 6 |
Amgen |
188.77 Bn |
176.74 Bn |
5.87 Bn |
| 7 |
Gilead Sciences |
160.22 Bn |
152.49 Bn |
5.52 Bn |
| 8 |
Pfizer |
148.19 Bn |
135.42 Bn |
-1.21 Bn |
| 9 |
Bristol Myers Squibb |
116.72 Bn |
106.26 Bn |
8.07 Bn |
| 10 |
Astrazeneca |
72.15 Bn |
64.21 Bn |
12.61 Bn |
| Date | Value |
|---|
| Mar 31, 2026 |
953,411.00 |
| Dec 31, 2025 |
20.49 Mn |
| Sep 30, 2025 |
10.37 Mn |
| Jun 30, 2025 |
14.75 Mn |
| Mar 31, 2025 |
385,937.00 |
| Dec 31, 2024 |
-302,790.00 |
| Sep 30, 2024 |
1.59 Mn |
| Jun 30, 2024 |
26.43 Mn |
| Mar 31, 2024 |
646,974.00 |
| Dec 31, 2023 |
277,106.00 |
| Sep 30, 2023 |
402,952.00 |
| Jun 30, 2023 |
158,508.00 |
| Dec 31, 2022 |
517,464.00 |
| Jun 30, 2022 |
25.90 Mn |
| Dec 31, 2021 |
135,564.00 |
| Sep 30, 2021 |
479,170.00 |
| Mar 31, 2021 |
675,067.00 |
| Dec 31, 2020 |
139,229.00 |
| Sep 30, 2020 |
889,548.00 |
| Jun 30, 2020 |
224,105.00 |
